These results, conducted in a population of patients with T2DM and established CV disease, while not definitive because of early study termination, nonetheless contribute to the existing dataset supporting the safety of the DPP-4 inhibitor drug class. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.